Attention deficit hyperactivity disorder: Pharmacologic management in children and adolescents

Gabriel Kaplan, Gabriel Kaplan, Jeffrey H. Newcorn, Iliyan S. Ivanov

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Attention deficit hyperactivity disorder (ADHD) used to be considered a mild childhood condition that manifested mostly in the school setting and remitted by adolescence. More recently, a large body of evidence has shown that it is a very frequent psychiatric problem in childhood, causes considerable suffering in patients and their families, and persists into adulthood in one form or other 50 - 70% of the time. This chapter outlines current pharmacological treatment options available to clinicians who wish to provide treatment for ADHD. Each US Food and Drug Administration (FDA)-approved agent is reviewed in detail focusing on the safety profile and efficacy data, as well as the monitoring tools that can be utilized to optimize treatment. Alternative non FDA-approved options are outlined as well. This review also addresses recent controversies in the field and provides practical clinical advice within a Frequently Asked Question format.

Original languageEnglish
Title of host publicationClinical Aspects of Psychopharmacology in Childhood and Adolescence, Second Edition
PublisherNova Science Publishers, Inc.
Pages51-75
Number of pages25
ISBN (Electronic)9781536102536
ISBN (Print)9781536102413
StatePublished - 1 Jan 2016

Fingerprint

Dive into the research topics of 'Attention deficit hyperactivity disorder: Pharmacologic management in children and adolescents'. Together they form a unique fingerprint.

Cite this